Pharmacological opportunities and pitfalls in the therapy of migraine

Current Opinion in Neurology

Volumn 14, Issue 3, 2001, Pages 341-346

  May, Arne ^a   Goadsby, Peter J ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; ACETYLSALICYLIC ACID; ALNIDITAN; ANTIMIGRAINE AGENT; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; ELETRIPTAN; ENDOTHELIN RECEPTOR ANTAGONIST; LANEPITANT; NARATRIPTAN; NEUROKININ 1 RECEPTOR ANTAGONIST; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; PNU 142633; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; VOFOPITANT; ZOLMITRIPTAN; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE;

CLINICAL TRIAL; DRUG EFFECT; HUMAN; MIGRAINE; NONHUMAN; REVIEW; TREATMENT FAILURE; TRIGEMINAL NERVE; VASOCONSTRICTION;

EID: 0034985740     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200106000-00012     Document Type: Review

References (92)

1. The mechanisms and treatment of migraine
2. Migraine and cutaneous vessels
3. Dual effect of dihydroergotamine and dihydroergotoxin in isolated human femoral veins and arteries
4. The mode of action of sumatriptan is vascular? A debate
5. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT 1-like receptor
6. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache
7. Brainstem effects on intra- and extracerebral circulations. Relation to migraine and cluster headache
8. Neurogenic inflammation in the pathophysiology and treatment of migraine
9. Response of brainstem trigeminal neurons to electrical stimulation of the dura
10. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
11. Sensitization of meningeal sensory neurons and the origin of headaches
12. Neuropeptides in the cerebral circulation: Relevance to headache
13. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain
14. The anti-migraine drug sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
15. The neurobiology of vascular head pain
16. Neurogenic vs. vascular mechanisms of sumatriptan and ergot akaloids in migraine
17. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache
18. Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery
19. 1D-like receptor
20. Naratriptan: Biological profile in animal models relevant to migraine
21. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilatation and extravasation
22. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
23. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
24. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches
25. Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine
26. Intracerebral arteries and gadolinium enhancement in migraine without aura
27. Transmitters involved in antinociception in the spinal cord
28. The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation
29. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles
30. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions
31. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain
32. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P
33. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
34. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs
35. Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater
36. The non-peptide neurokinin-1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats
37. Comparison of the effects of sumatriptan and the NK-1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos RNA expression in trigeminal nucleus caudalis of rats
38. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva
39. The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation
40. Selective blockade of substance P or neurokinin A receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat
41. Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig
42. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system
43. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation
44. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater
45. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks
46. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks
47. Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study
48. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine
49. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine
50. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery
51. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist
52. ET and EDRF ... Implications for migraine
53. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide
54. Raised plasma endothelin-I concentration following cold pressor test
55. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
56. Raised plasma endothelin during acute migraine attack
57. Endothelin 1 in migraine and tension-type headache
58. Endothelin in migraine patients
59. Plasma endothelin during upright tilt: Relevance for orthostatic hypotension?
60. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors
61. Lysine-acetylsalicylic acid in acute migraine attacks
62. Nitric oxide mechanisms in migraine
63. Nitric oxide is a key molecule in migraine and other vascular headaches
64. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats
65. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
66. Neuropeptides in migraine and cluster headache
67. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion
68. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro
69. The trigeminovascular system in humans: Pathopysiological implications for primary headache syndromes of the neural influences of the cerebral circulation
70. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies
71. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
72. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack
73. Neuropeptide changes in a case of chronic paroxysmal hemicrania: Evidence for trigemino-parasympathetic activation
74. Expression of calcitonin gene-related peptide1 receptor mRNA in human trigeminal ganglia and cerebral arteries
75. Functional calcitonin gene-related peptide type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, and cerebromicrovascular or astroglial cells in culture
76. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat
77. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
78. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist
79. Effect of sumatriptan on sensory neurotransmission in guinea-pig basilar artery
80. Presynaptic inhibitory action of 5HT in dog isolated saphenous vein
81. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism
82. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption
83. Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH: Inhibition by the serotonin (5-HT1) receptor agonist CP 93,129
84. In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid
85. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides
86. A study of safety and efficacy in patients with acute migraine, using PNU-142633, a selective 5-HT1D agonist
87. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study
88. Changes of cerebral blood flow velocity after treatment of migraine with sumatriptan, erotamine, acetylsalicylic acid or placebo
89. Acetylsalicylic acid effervescent 1000 mg (aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study
90. Cardiovascular safety of 5HT1B/1D agonists: Is there a cause for concern?